Remifentanil deal builds Paion's anaesthesia prospects
This article was originally published in Scrip
Executive Summary
The German firm Paion has signed a deal for the German distribution rights of the generic anaesthesia product remifentanil. It says the ultra short-acting opioid is an ideal companion product for the anaesthesia/sedative drug candidate remimazolam, on which it decided earlier this year to focus in a strategic realignment around anaesthesia and critical care (scripintelligence.com, 29 February 2012).
You may also be interested in...
Big Pharma’s Aging Antibodies Cling To Their Crowns
The best-seller rankings today are testament to the great success of antibody drug technology developed at the end of the last century, and contrast with the dominance of primary care small molecule drugs that powered big pharma in previous decades. But where did these drugs come from – and where are they going?
Novartis To Pay $9.7bn For The Medicines Company
Novartis is to acquire the Phase III siRNA drug inclisiran in a cash deal that swells its cardiovascular portfolio. The move will not be welcomed by Amgen, Sanofi or Regeneron.
Deal Watch: Molecular Templates Aligns With Vertex On Optimizing Stem Cell Candidates
Alliance with Molecular Templates may help advance efforts under Vertex’s existing collaboration with CRISPR Therapeutics. Dragonfly’s latest partner for its TriNKET platform is AbbVie.
Need a specific report? 1000+ reports available
Buy Reports